Anticancer Activity and Apoptotic Effects of Bulnesia sarmienti Against Human Lung Cancer H460 Cells

Author(s):  
Mohammad Lalmoddin Mollah ◽  
Jae-Chan Song ◽  
Chang-Ho Park ◽  
Gee-Dong Lee ◽  
Joo-Heon Hong ◽  
...  
2021 ◽  
Vol 54 (1) ◽  
Author(s):  
Somruethai Sumkhemthong ◽  
Eakachai Prompetchara ◽  
Pithi Chanvorachote ◽  
Chatchai Chaotham

Abstract Background Accumulated evidence demonstrates cisplatin, a recommended chemotherapy, modulating pro-survival autophagic response that contributes to treatment failure in lung cancer patients. However, distinct mechanisms involved in cisplatin-induced autophagy in human lung cancer cells are still unclear. Results Herein, role of autophagy in cisplatin resistance was indicated by a decreased cell viability and increased apoptosis in lung cancer H460 cells pre-incubated with wortmannin, an autophagy inhibitor, prior to treatment with 50 µM cisplatin for 24 h. The elevated level of hydroxyl radicals detected via flow-cytometry corresponded to autophagic response, as evidenced by the formation of autophagosomes and autolysosomes in cisplatin-treated cells. Interestingly, apoptosis resistance, autophagosome formation, and the alteration of the autophagic markers, LC3-II/LC3-I and p62, as well as autophagy-regulating proteins Atg7 and Atg3, induced by cisplatin was abrogated by pretreatment of H460 cells with deferoxamine, a specific hydroxyl radical scavenger. The modulations in autophagic response were also indicated in the cells treated with hydroxyl radicals generated via Fenton reaction, and likewise inhibited by pretreatment with deferoxamine. Conclusions In summary, the possible role of hydroxyl radicals as a key mediator in the autophagic response to cisplatin treatment, which was firstly revealed in this study would benefit for the further development of novel therapies for lung cancer.


2019 ◽  
Vol 2019 ◽  
pp. 1-11 ◽  
Author(s):  
Juan Sebastian Yakisich ◽  
Neelam Azad ◽  
Vivek Kaushik ◽  
Anand K. V. Iyer

The biguanides metformin (MET) and to a lesser extent buformin (BUF) have recently been shown to exert anticancer effects. In particular, MET targets cancer stem cells (CSCs) in a variety of cancer types but these compounds have not been extensively tested for combination therapy. In this study, we investigated in vitro the anticancer activity of MET and BUF alone or in combination with 2-deoxy-D-glucose (2-DG) and WZB-117 (WZB), which are a glycolysis and a GLUT-1 inhibitor, respectively, in H460 human lung cancer cells growing under three different culture conditions with varying degrees of stemness: (1) routine culture conditions (RCCs), (2) floating lung tumorspheres (LTSs) that are enriched for stem-like cancer cells, and (3) adherent cells under prolonged periods (8-12 days) of serum starvation (PPSS). These cells are highly resistant to conventional anticancer drugs such as paclitaxel, hydroxyurea, and colchicine and display an increased level of stemness markers. As single agents, MET, BUF, 2-DG, and WZB-117 potently inhibited the viability of cells growing under RCCs. Both MET and BUF showed a strong synergistic effect when used in combination with 2-DG. A weak potentiation was observed when used with WZB-117. Under RCCs, H460 cells were more sensitive to MET and BUF and WZB-117 compared to nontumorigenic Beas-2B cells. While LTSs were less sensitive to each single drug, both MET and BUF in combination with 2-DG showed a strong synergistic effect and reduced cell viability to similar levels compared to the parental H460 cells. Adherent cells growing under PPSS were also less sensitive to each single drug, and MET and BUF showed a strong synergistic effect on cell viability in combination with 2-DG. Overall, our data demonstrates that the combination of BGs with either 2-DG or WZB-117 has “broad-spectrum” anticancer activities targeting cells growing under a variety of cell culture conditions with varying degrees of stemness. These properties may be useful to overcome the chemoresistance due to intratumoral heterogeneity found in lung cancer.


Life Sciences ◽  
2004 ◽  
Vol 75 (18) ◽  
pp. 2233-2244 ◽  
Author(s):  
Xiaolu Yin ◽  
Jiangbing Zhou ◽  
Chunfa Jie ◽  
Dongming Xing ◽  
Ying Zhang

2018 ◽  
Vol 3 (29) ◽  
pp. 8468-8472 ◽  
Author(s):  
Devendra Pratap Mishra ◽  
Mohsin Ali Khan ◽  
Dinesh Kumar Yadav ◽  
Arun Kumar Rawat ◽  
Rakesh Kumar Singh ◽  
...  

2009 ◽  
Vol 180 (2) ◽  
pp. 165-174 ◽  
Author(s):  
Bing-Sang Wong ◽  
Yung-Chin Hsiao ◽  
Ta-Wei Lin ◽  
Kuo-Shuen Chen ◽  
Pei-Ni Chen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document